Hematology: Fas determines outcome in DLBCL

Abstract

Diffuse-large B-cell lymphoma (DlBCl) is a particularly aggressive form of non-Hodgkin lymphoma. CHoP chemotherapy and rituximab have increased the response rates and survival outcomes in elderly patients with DlBCl. many investigators have tried to identify prognostic factors for such patients to distinguish those with a favorable or unfavorable outcome and to select appropriate treatment strategies.

DOI: 10.1038/nrclinonc.2009.178

Cite this paper

@article{Hutchinson2009HematologyFD, title={Hematology: Fas determines outcome in DLBCL}, author={Lisa Hutchinson}, journal={Nature Reviews Clinical Oncology}, year={2009}, volume={6}, pages={677-677} }